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S U M M A R Y
Tuberculosis (TB) is a leading cause of global morbidity, yet there is limited information regarding its
impact on quality of life and health status. This is surprising given the implications for patient care, the
evaluation of novel treatments or preventative strategies, and also health policy. Furthermore, there is no
validated TB-speciﬁc instrument that measures health status, and thus a wide and non-standardized
range of assessment tools have been employed. The studies to date have chosen a number of different
comparator populations, and in many TB endemic areas there is a lack of normative data regarding the
health status of the general population. Systematic evaluations of quality of life are urgently needed in
speciﬁc groups, including those with extrapulmonary TB, drug-resistant disease, HIV co-infection, and
latent TB infection, and in children with TB; the assessment of post-treatment disability is also required.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
The suffering caused by tuberculosis (TB) has been acknowl-
edged for millennia,1 though the systematic evaluation of health-
related quality of life (HRQOL) is a much more recent develop-
ment.2 TB is a leading cause of morbidity in many regions, and as
such an understanding of its effect on quality of life and health
status is important for patient care, the evaluation of novel
treatments or preventative strategies, and also for health policy, as
data on quality of life are used within health economic evaluations.
Several difﬁculties arise when assessing quality of life in TB: there
is no validated TB-speciﬁc instrument that measures health status,
and there are difﬁculties in choosing appropriate comparator
populations and a lack of normative data on health status for the
general population in many TB endemic areas. Furthermore, there
are few systematic evaluations of quality of life in speciﬁc groups,
such as those with extrapulmonary TB, drug-resistant disease, HIV
co-infection, and latent TB infection (LTBI), or in children with TB.
These make ‘health status’ summaries in TB difﬁcult, probably* Corresponding author. Tel.: +44 207 317 7561.
E-mail address: james.brown.14@ucl.ac.uk (J. Brown).
http://dx.doi.org/10.1016/j.ijid.2014.12.045
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).inaccurate, and can undermine the validity of cost-effectiveness
studies of TB management.
Impairment in HRQOL is a complex construct of inﬂuences
including physical, mental, and social well-being3 – thus illness is
experienced by individuals, yet cannot be understood indepen-
dently of the societies in which people live.4 Although a biological
deﬁnition of TB infection (i.e., latent TB) or disease (active TB) may
be universal, it is not possible to produce a single numerical value
that summarizes the impact of TB on an individual. It is not
surprising, therefore, that quantitative studies have reported a
wide range of values for the health impairment associated with TB
before, during, and after treatment.5 In this review we will
summarize the evidence regarding quality of life in TB, highlight
areas where there is limited information available, and discuss its
importance in relation to health economic evaluations.
2. Instruments used to measure health-related quality of
life in TB
Evaluations of HRQOL can utilize generic tools applicable to
many conditions, or speciﬁc measures designed to evaluate a
particular disease or organ system. Both strategies have advantages,
and a combination of generic and speciﬁc tools is often helpful.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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TB, though none are designed speciﬁcally for TB (Table 1).
The choice of population against which to compare the HRQOL
in those with TB is important. TB often preferentially affects
disadvantaged groups or particular ethnic minorities, and hence
comparisons of HRQOL with those in the general population may
be misleading. An ideal comparator group would be identical in
all respects, other than the absence of TB. Those with LTBI
represent an attractive group for such comparisons, as they
are likely to have similar backgrounds and hence cultural
understanding of illness, in particular TB, and by deﬁnition do
not have symptoms of active disease. However a diagnosis of
LTBI may itself be associated with a reduction in health statusTable 1
Instruments used to assess quality of life in TB
Name of instrument Comments
General quality of life instruments
Brief Disability Questionnaire (BDQ) 11-item scale; hi
Duke Health Proﬁle (DUKE) 63 items evaluati
better HRQOL
Dysfunctional Analysis Questionnaire (DAQ) 50 items evaluat
indicate worse H
Euro-QoL (EQ 5D) 5 domains each 
General Health Questionnaire 12 (GHQ 12) Modiﬁed version
scale; higher sco
Health Utilities Index 2 (HUI 2) 7 items, each wit
(perfect health)
Health Utilities Index 3 (HUI 3) 8 items, each wit
(perfect health)
Life Satisfaction Index Z 13 items, total sc
Present State Examination (PSE) Combined genera
worse HRQOL
SF-36 Health Survey (SF-36) 36 items covering
greater HRQOL
SF-12 Health Survey Abbreviated form
SF-6D utility score 11-item measure
HRQOL
Sheehan Disability Scale (SDS) 20 items evaluati
HRQOL
Sickness Impact Proﬁle (SIP) 136 items evalua
dysfunction
Severe Respiratory Insufﬁciency Questionnaire (SRI) 49 items ranked 
physical and soc
Standard Gamble Subjects chose be
of perfect health 
higher scores ind
Symptoms Check List (SCL-90) 90 items in 9 do
symptom total, a
Visual Analogue Scale (VAS) Subjects mark on
10 cm = perfect h
World Health Organization’s Quality of Life–BREF
(WHOQOL-BREF)
26 items compri
environment) ran
Instruments assessing psychological morbidity
Beck Depression Inventory (BDI) 21-item question
depression, with
Beck Depression Inventory (BDI Short Form) 13-item question
depression, 4– 7 
Hospital Anxiety and Depression Scale (HAD) 14 items evaluat
Rosenberg Self-Esteem Scale (RSE) 10 items each w
Mood Adjective Check List Short Form (MACL) 38 items evaluat
Self-Rating Anxiety Scale (SAS) 20 items with a 
Centre for Epidemiologic Studies Depression Scale (CES-D) 15 items each w
Kessler 10 10 items assessin
better HRQOL
State-Trait Anxiety Inventory Short Form (STAI-6) 6 items with a 4
Disease or system-speciﬁc instruments
St. George Respiratory Questionnaire Short Form (SGRQ) 50 items in 3 do
originally develo
World Health Organization’s Quality of Life – HIV
(WHOQOL-HIV)
Modiﬁed version
HRQOL
DR-12 TB-speciﬁc qualit
better HRQOL
MOS-HIV 35-item question
HRQOL, health-related quality of life.caused by anxiety or stigmatization, or the adverse effects of
medication.6
3. Quality of evidence about quality of life in TB
Systematic reviews by Chang et al.,7 Guo et al.,8 and Bauer et al.5
provide an appraisal of the available evidence regarding quality of
life in those with TB. The most recent of these (which contains a
literature search up to April 2011) evaluates 38 articles describing
28 unique study cohorts comprising 6028 patients. However,
assessment of the quality of the primary studies suggests that
signiﬁcant risks of bias may be present. In addition, the
psychometric properties of the instruments used are often notgher scores indicate worse HRQOL
ng symptoms and physical, social, and emotional function; higher scores indicate
ing social, vocational, personal, familial, and cognitive domains; higher scores
RQOL
ranked with a 3-point scale; higher scores indicate better HRQOL
 of the General Health Questionnaire 60. Each item ranked with a 4-point Likert
res indicate worse HRQOL
h 3 to 5 levels, used to calculate overall health utility function from 0 (death) to 1
h 5 to 6 levels, used to calculate overall health utility function from 0 (death) to 1
ores range from 0 to 26, with higher scores indicating better HRQOL
l health questionnaire and self-rating depression scale; higher scores indicate
 physical and mental wellbeing. Scores from 0–100, with higher scores indicating
 of the SF-36
 of health status. Scores range from 0 to 1.0, with higher scores indicating better
ng work, family, and social lives. Scores from 0 to 30; higher scores indicate worse
ting personal and social impact of illness; a score of >10 indicates severe
with a 5-point Likert scale evaluating respiratory complaints and associated
ial limitations; higher scores indicate better HRQOL
tween a given health state and an imaginary gamble between possible outcomes
and death; results are used to calculate a HRQOL score ranging from 0 to 1, with
icating better HRQOL
mains used to calculate three global indices of global severity index, positive
nd positive symptom distress index; higher scores indicate worse HRQOL
 a scale where they rate their own health, either using a 10-cm scale (0 cm = death,
ealth) or a 100-cm ‘feeling thermometer’
sing 5 domains (physical health, psychological health, social relationships,
ked on a 5-point Likert scale; higher scores indicate better HRQOL
naire designed to evaluate depression; higher scores indicate more severe
 a cut-off of 13 used to indicate depression
naire evaluating the presence of depression; overall score 0–3 = none or minimal
= mild depression, 8–15 = moderate depression, 16 = severe depression
ing anxiety and depression; higher scores indicate more anxiety/depression
ith a 4-point scale evaluating self-esteem
ing three psychological domains (pleasantness, activation, calmness)
4-point Likert scale evaluating anxiety; higher scores indicate worse HRQOL
ith a 4-point Likert scale; higher scores indicate more severe depression
g psychological distress, each with a 5-point Likert scale; higher scores indicate
-point scale used to evaluate anxiety
mains (symptoms, activity, and impacts) speciﬁc to respiratory illnesses and
ped to assess patients with airways disease
 of the WHOQOL-100 used for patients with HIV; higher scores indicate better
y of life score with 12 items each ranked on a scale of 1–3; higher scores indicate
naire validated to assess quality of life in HIV-infected individuals
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ceiling and ﬂoor effects in the instruments used (i.e., that a very
large proportion of respondents have the highest or lowest
possible response to a particular variable), and where they do,
signiﬁcant effects are noted: for instance over 50% of those with
concurrent or previous TB reported the highest scores for ﬁve of the
SF-36 subscales in the study by Dion et al.9
Bias by language of patients may be a signiﬁcant issue in
evaluating quality of life, particularly in settings where subjects
come from diverse migrant populations.10 Several studies were
only able to assess patients who spoke the language of the
investigators – for instance of 411 charts screened for potential
inclusion in a study from Canada, one-third were excluded because
of their inability to speak English or French.11 Similarly, the study
of Kruijshaar and Abubakar only included those who spoke
adequate English, and although the number of patients unable to
participate because of language barriers is not described, the
authors comment that selection bias could have occurred.12
The use of written self-administered questionnaires raises
difﬁculties where subjects do not have sufﬁcient literacy and may
introduce bias from varied levels of reading comprehension.
Pasipanodya et al. therefore chose to administer the St. Georges
Respiratory Questionnaire (SGRQ) by reading translations of the
questionnaire in the language of the subject.13 Although this deals
with the difﬁculty of reading comprehension bias, the SGRQ has
not been validated as an interviewer-administered tool and may
yield different results when used this way.
4. Health status impairment associated with TB and the effect
of treatment
At least 40 different papers from 16 countries (primarily in the
developing world) provide information on health status or qualityTable 2
Studies providing cross-sectional data
Author [Ref.] Year
published
Location HRQOL assessment
instrument useda
Westaway [16] 1992 South Africa Abbreviated BDI, RSE 
Wang [63]b 1998 China SF-36, QLI, KPS 
Aghanwa [17] 1998 Nigeria GHQ-30 
Bhatia [64] 2000 India DAQ 
Aydin [15] 2001 Turkey GHQ-12 
Yang [65]b 2003 China SCL-90 and Social Support
Rating Scale (SSRS)
Dion [11] 2004 Canada VAS and Standard Gamble 
Vinaccia [66]b 2007 Colombia SF-36 
Pasipanodya [13] 2007 USA SGRQ 
Muniyandi [33] 2007 India SF-36 
Guo [8] 2008 Canada SF-36, HUI2/3, and a general
health VAS
Unalan [67] 2008 Turkey SF-36, BDI 
Husain [68] 2008 Pakistan HAD, Illness Perception
Questionnaire
Dhuria [69] 2009 India WHOQOL-BREF (Hindi version) 
Babikako [37] 2010 Uganda 35-item MOS instrument, VAS 
Chung [70] 2012 Taiwan Taiwan short version of the
WHOQOL-BREF
Godoy [45] 2012 Brazil Asthma Questionnaire 20 Score 
Louw [41] 2012 South Africa SF-12 
Masumoto [14] 2014 Philippines Short Form-8, Duke-UNC
Functional Social Support
Questionnaire, and
Medical Research Council
(MRC) dyspnoea scale
HRQOL, health-related quality of life; TB, tuberculosis; VAS, visual analogue scale; MD
a For details of the instruments used, see Table 1.
b Full text not available in English, or only published in abstract form.of life for those with TB. Most give cross-sectional data only, and
many do not include a comparator population (Table 2).63–70
Instruments differ in the dimensions used, with some evaluating
physical health, some speciﬁcally measuring psychological mor-
bidity, and others attempting a holistic assessment of HRQOL.
Therefore, different instruments evaluate different effects of TB.
Studies that utilize instruments such as the SF-36 that include both
physical and psychological domains, conﬁrm that signiﬁcant
deﬁcits in psychological wellbeing exist alongside physical
complaints. This is also reported by a number of other
studies.8,14–17,25
When active TB is compared to a comparator population, the
evidence suggests that active TB is associated with a lower health
status than found in subjects without TB or with LTBI. For example,
Guo et al. described the difference in SF-36 scores between those
with latent and active TB in Canada and found a worse mean
Physical Component Summary (PCS) score of 44.8 and Mental
Component Summary (MCS) score of 40.1 in those with active TB,
compared to a mean PCS score of 54.7 and MCS score of 50.3 in
those with latent TB.8
There is less information available about longitudinal changes
in health status with treatment (Table 3). Only two studies (one
from the UK and the other from Canada) provide data from
developed countries, in which TB primarily affects migrant
populations. The study by Kruijshaar et al.18 in the UK followed
patients at diagnosis and at 2 months, and the study by Marra et al.
in Canada assessed patients at diagnosis and at 6 months.19 Both
used the SF-36 alongside other instruments and both identiﬁed
improvements in quality of life with treatment – although in
neither case was the improvement sufﬁcient to reach population
norms. Kruijshaar et al. assessed the change between baseline and
2 months and reported only a small improvement in the PCS score
of the SF-36 (36 to 39 points; p = 0.167), but a greater improvementSite of disease Number
with
active TB
Number
with
latent TB
Number of
healthy
controls
% HIV-positive
Pulmonary 100 0 0 Not stated
Pulmonary 228 0 228 Not stated
Pulmonary 53 0 40 Not stated
Not stated 50 0 0 Not stated
Pulmonary 119 0 38 Not stated
Pulmonary 132 0 71 Not stated
Not stated 17 25 0 All HIV-negative
Pulmonary 60 0 0 Not stated
Pulmonary 105 207 0 9.6% HIV-positive
Pulmonary and
extrapulmonary
436 0 0 Not stated
Not stated 84 78 0 Not stated
Not stated 196 196 Not stated
Not stated 108 0 0 Not stated
Not stated 90 0 90 Not stated
Pulmonary 133 0 0 50% HIV-positive
Pulmonary 140 0 130 Not stated
Pulmonary,
MDR TB
18 0 0 All HIV-negative
Not stated 4900 0 0 60% HIV-positive
Pulmonary 561 0 0 Not stated
R, multidrug-resistant.
Table 3
Studies providing prospective follow-up
Author [Ref.] Year
published
Site Time-points
assessed
Scales used Site of disease Number
with
active TB
Number
with
latent TB
Number of
healthy
controls
HIV status
Chamla [25] 2004 China Baseline, 2 months,
end of treatment
SF-36 Pulmonary and
extrapulmonary
102 0 103 Not stated
Rajeswari [20] 2005 India 2 months and 6 months SF-36 Not stated 610 0 0 Not stated
Marra [19] 2008 Canada Baseline, 3 months,
and 6 months
SF-36 and the BDI Pulmonary and
extrapulmonary
104 102 0 8% HIV-positive
Maguire [24] 2009 Indonesia Baseline, 2 months,
and 6 months
Modiﬁed SGRQ Pulmonary 115 0 0 4.50% HIV-positive
Kruijshaar [18] 2010 UK Diagnosis and 2 months SF-36 and EQ-5D Pulmonary and
extrapulmonary
61 0 0 Not stated
Bauer [6]b 2012 Canada Treatment initiation
and 2 months
SF-36, Standard
Gamble
Pulmonary and
extrapulmonary
60 118 106 Not stated
Deribew [39] 2013 Ethiopia Baseline and 6 months WHOQOL-HIV Not stated 124 0 465 All HIV-positive
Atif [26] 2014 Malaysia Baseline, end of
intensive phase,
end of treatment
SF-36 Pulmonary 216 0 0 All HIV-negative
TB, tuberculosis.
a For details of the instruments used, see Table 1.
b Only published as abstract.
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with a reduction in rates of anxiety and depression.18 Marra et al.
reported a mean 10-point difference in SF-36 MCS and 6.4-point
difference in PCS between those with active and latent TB, which
narrowed to differences of 3.71 for MCS and 4.3 for PCS by
6 months.19
Studies from India,20–23 Indonesia,24 China,25 and Malaysia26
provide data on changes in quality of life with treatment for TB in
the TB endemic areas. Again, such studies demonstrate improve-
ments, but show residual deﬁcits in quality of life and health status
compared to those with latent TB, those without TB, or population
norms. Atif et al. studied 216 individuals with pulmonary TB in
Malaysia and reported an improvement in PCS score from 41.9 at
baseline to 46 after 6 months, with an improvement in MCS from
39.9 to 46.8.26 Maguire et al. described changes in health status
using a modiﬁed SGRQ in 115 patients with smear-positive
pulmonary TB in Indonesia. The participants had a mean SGRQ
score of 45.4 at baseline, and 94% had an improvement of at least
4 points (considered the minimum clinically important difference
in the SGRQ) by 2 months of treatment. Eighty percent had further
signiﬁcant improvement between 2 months and 6 months.24
5. Exploring the causes of impaired health status
Qualitative research methodologies may provide insight into
the experiences of those with TB and illuminate causes of reduced
quality of life. For example a study from Brazil conducted
interviews with patients who had completed TB treatment to
determine life experiences with TB.27 This demonstrated signiﬁ-
cant levels of anxiety and stigmatization, which were in part
heightened by inaccurate beliefs concerning the aetiology and
transmissibility of TB. Studies evaluating the impact of TB on
quality of life have focused on assessments made whilst
individuals are on treatment. This neglects the impact at other
stages of disease – for instance those with TB may have symptoms
for several months prior to diagnosis. Also, in addition to physical
and psychological harm, individuals can encounter stigmatization
and social isolation. Once diagnosed, the adverse effects of anti-TB
medication can be considerable. In addition, individuals may face
extra costs accessing care and obtaining medication whilst
experiencing loss of employment. When treatment is completed,
many can have long-term physical sequelae of TB, which in some
cases result in life-long impairment (and further stigma).Differences in treatment strategies vary considerably between
health systems in ways that may affect quality of life. For instance
the majority of patients treated in Germany are initially hospital-
ized (with an average length of stay of 30 days in 201128), whilst in
the UK clinical guidelines advise against routine hospital admis-
sion.29 Although supervised therapy is strongly advocated by the
World Health Organization directly observed therapy strategy
(WHO DOTS)30 and might improve quality of life by improving
outcomes, it may also make employment more difﬁcult or enhance
stigmatization. The use of ambulatory care is encouraged in
current guidelines for the management of multidrug-resistant
(MDR)-TB,31 although its effect on quality of life is unknown.
Very little information is available regarding the long-term
quality of life of those who have completed TB treatment and none
of the studies that collected longitudinal data during TB treatment
included follow-up post treatment completion. Pasipanodya et al.
documented respiratory symptoms using the SGRQ in 100 subjects
with pulmonary TB who had completed at least 20 weeks of TB
treatment in Texas, with the aim of evaluating pulmonary
impairment after TB; they noted a signiﬁcant increase in SGRQ
score (i.e., worse health status) compared to those with latent TB.13
Subjects with the greatest deﬁcits in lung function had higher
SGRQ scores (indicating greater impairment).
Although TB can be associated with the development of long-
term complications (including bronchiectasis, airﬂow obstruction,
and restrictive pulmonary function deﬁcits in the case of
pulmonary TB), the long-term effect of these changes on quality
of life has not been assessed, and cost-effectiveness studies have
often assumed a return to normal quality of life on completion of
TB treatment.32 Although an assessment of SF-36 scores 1 year
after TB treatment in India did in fact suggest scores were
comparable with population norms,33 this is likely to be
inaccurate, and conﬂicts with other data.34
6. Quality of life in speciﬁc groups
Estimating how much TB impacts on quality of life is essential
for analyses of cost effectiveness. However, it is responsible for a
diverse variety of clinical problems – each of which may have a
variable impact on the affected individual. We consider the current
evidence regarding health status in adults with latent TB,
extrapulmonary TB, drug-resistant TB, and HIV–TB co-infection,
and the impact of TB on children.
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Health status and the effect of treatment for LTBI is important,
as the population at risk is many times larger than that with active
TB, and successful strategies to reduce the global burden of TB may
need to greatly increase rates of latent TB treatment.35
Those with latent infection by deﬁnition do not have symptoms
associated with TB, yet by being given a diagnostic label may feel
social stigmatization or anxiety. Furthermore, treatment can result
in adverse events with no perceived short-term beneﬁt to the
patient (beyond a potential reduction in anxiety about TB after
completing treatment). The harms of diagnosis and treatment of
LTBI must be balanced against the beneﬁts of a reduced incidence
of active TB. It should be noted that Bauer et al. found a reduction in
HRQOL associated with LTBI treatment compared to healthy
controls.6 Unfortunately, randomized trials comparing LTBI
treatment regimens have not included quality of life evaluations,
and it is therefore difﬁcult to report comparisons of the currently
available regimens.
6.2. Extrapulmonary TB
Distinguishing extrapulmonary from pulmonary TB seems
important, although health status is also likely to be related to the
predominant anatomical site of disease. For example, the impact
of isolated TB lymphadenitis is likely to be very different to, for
instance, TB meningitis. Unfortunately as many studies of quality
of life in TB have not reported results stratiﬁed by disease site,
this is often difﬁcult to quantify. Dhingra and Rajpal reported
longitudinal data from a cohort of 51 patients with pulmonary TB
and 25 patients with extrapulmonary TB treated in India22 and
identiﬁed a lower quality of life score in those with extra-
pulmonary TB, despite the fact that several questions in the
instrument used were speciﬁc to pulmonary disease. Conversely,
Chamla reported from China no signiﬁcant difference in SF-36
score in those with pulmonary and extrapulmonary TB,25 but no
details on the numbers with extrapulmonary TB or their sites of
disease were provided. In summary, the paucity of evidence
regarding quality of life in extrapulmonary TB means that we are
still, by and large, at a level where we assume that some forms of
extrapulmonary TB are associated with signiﬁcant morbidity and
long-term disability, although we have little evidence to conﬁrm
or refute this.
6.3. HIV–TB co-infection
An estimated 13% of those with TB also have an HIV infection.10
The combination of these two conditions, both often subject to
signiﬁcant stigmatization, is of particular importance.36 TB–HIV
co-infection presents unique challenges and could be expected to
have signiﬁcant implications for quality of life. Unfortunately,
many studies have either excluded those with HIV infection, or
have not reported the HIV status of their subjects, and few have
speciﬁcally evaluated this question. The impact of antiretroviral
therapy (ART) usage also needs to be accounted for.
Babikako et al. explored quality of life using a translated and
culturally adapted version of the 35-item Medical Outcomes Study
instrument in Uganda in 133 patients with pulmonary TB, 50% of
whom were HIV co-infected.37 This cross-sectional study selected
participants from both public and private hospital settings who
were either starting anti-TB treatment or had completed 2 or
8 months of therapy. It demonstrated signiﬁcant improvements
with treatment: for instance mean visual analogue scale (VAS)
scores were 60.7, 67.1, and 78.5 at baseline, 2 months, and
8 months, respectively. There was no signiﬁcant difference in
quality of life in those with and without HIV co-infection, althoughthe authors did not appear to evaluate or account for the impact of
ART on quality of life in those with HIV–TB co-infection.
Deribew et al. studied 124 HIV-positive individuals with TB and
465 without TB in Ethiopia using an Amharic version of the World
Health Organization Quality of Life Instrument for HIV-infected
people.38,39 Those with HIV–TB demonstrated greater improve-
ments in quality of life after 6 months of follow-up: in those with
TB, scores for the physical health domain improved by a mean of
5.1 points, compared to a mean 0.7 points in subjects with HIV
alone. However those selected as controls were drawn from a
clinically stable HIV population and were taking antiretrovirals.
Hence, in contrast to the HIV–TB patients, they are unlikely to have
had much in the way of change in their quality of life over time. The
strongest predictor of reduced quality of life was the presence of
mental health issues (assessed by the Kessler 10 scale). Once more,
this study was not able to measure the inﬂuence of ART on quality
of life.
Work by Dowdy et al. in Brazil compared 45 HIV-positive adults
with 44 individuals with TB and nine with both conditions using
the MOS-HIV and a VAS.40 Similar scores were found in the three
groups, with only the physical health summary scores in those
with HIV–TB compared to those with HIV alone being signiﬁcantly
different. In an evaluation of 4900 participants with TB in South
Africa, 59% of whom were HIV co-infected, HIV infection was
associated with a signiﬁcantly lower health status as assessed by
the SF-36 (for instance the mean PCS score in those with HIV–TB
was 39.4 compared to 42.5 in the HIV-negative patients with TB).
The use of ART was associated with a lower quality of life in the
multivariable analysis, although this did not reach statistical
signiﬁcance.41 The interpretation of results concerning ART within
such an observational study is not straightforward, as individuals
with worse immunocompromise (who might be expected to have a
reduced quality of life) are generally more likely to be offered ART.
6.4. Quality of life in MDR-TB
The complexity and duration of treatment, high rates of adverse
events, additional stigmatization, and difﬁculties with family life,
fertility, and employment would imply that quality of life will be
particularly impaired in those with MDR and extensively drug-
resistant (XDR) TB.42 Globally, an estimated 5% of TB is MDR,
representing around 480 000 cases in 2013. This is unevenly
distributed, with particularly high rates in some regions resulting
in speciﬁc challenges in these areas.10
Perhaps because of the high mortality associated with MDR-
TB,43 especially in regions where many patients also have HIV co-
infection,44 less attention has been given to quality of life
evaluation in these populations and very little evidence is available
in those with MDR-TB. In one of the few reports available, Godoy
et al. utilized the AQ20 to measure respiratory symptoms in
18 patients who had completed at least 18 months of treatment for
MDR-TB in Brazil, alongside comprehensive respiratory assess-
ment including the 6-minute walk test, lung function tests, and
chest radiographs.45 They reported a reduction in AQ20 score
(higher scores indicating worse symptoms), but there was a very
wide range (from 0 to 18, maximum = 20), and the relationship
between these scores and the physical disabilities of the
participants was not reported. In addition, it should be noted that
this instrument was designed to be utilized in asthma and its use in
the context of TB has not been validated.
Treatment regimens for MDR-TB involve many months of
complex drug combinations, including extended periods with
injectable medications. These regimens are associated with
signiﬁcant adverse effects, in particular irreversible hearing loss
and symptomatic peripheral neuropathies, which affect a signiﬁ-
cant proportion of patients treated for MDR-TB, even with careful
Table 4
What would be included in an ideal study of quality of life in TB?
Study feature Characteristics
Instrument(s) Able to capture all health-related physical impairment
(i.e., not organ- or system-speciﬁc)
Able to evaluate psychological morbidity associated with
TB
Culturally and linguistically appropriate for the study
population
Includes evaluation of social role limitations and stigma
Simple to administer
Repeatable over time
Study population Representative of the population at risk of TB, including,
as far as possible, groups that are often neglected (e.g.,
HIV-positive individuals, children, pregnant women, and
hard to reach groups such as the homeless and those with
substance abuse problems)
Study design Prospective design with data collection at deﬁned time-
points (e.g., baseline, end of intensive phase of treatment,
end of treatment, and deﬁned follow-up point)
Includes evaluation of residual impairment in quality of
life after treatment and change in health-related quality
of life after a period of follow-up
Reporting of results Includes a description of the following parameters: site of
disease, age, gender, ethnicity, and HIV status of
participants
Includes analyses of comorbidities (such as diabetes,
renal failure, and HIV) and cofactors (such as smoking and
socioeconomic status) that may inﬂuence quality of life
TB, tuberculosis.
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associated with high rates of psychological comorbidity –
symptoms of anxiety and depression being present in many
patients. Furthermore, hospitalization, stigma, and difﬁculties in
maintaining family life mean that people with drug-resistant TB
often become socially isolated and lose the support networks that
are key to the maintenance of health status.
In addition to the medication used to manage MDR-TB, the
delivery of services has a major impact on outcome and hence
quality of life. Many health systems have responded to MDR-TB
with models of care that have included prolonged periods of
hospitalization. Of note here, organized ambulatory care appears
to have at least equivalent long-term outcomes49 and may also
result in improved quality of life, although studies reporting health
status using alternative models of care are limited.49
6.5. TB infection and quality of life in children and other high-risk
groups
An estimated 550 000 children developed TB in 2013.50 In
addition, TB affecting parents and care-givers has a signiﬁcant
impact on the quality of life of children, particularly as it tends to
affect those of working and childbearing age. However, there has
been little structured evaluation of these effects: the systematic
review of the literature up to 2011 by Bauer et al. could not identify
any studies that included participants under the age of 11 years.5
Other speciﬁc groups of individuals at risk of TB are worthy of
consideration: extremely high rates of TB infection are reported in
speciﬁc groups in some settings, for instance health-care work-
ers51–53 and prisoners.54 TB is increased in pregnancy and the
postpartum period,55 and is associated with adverse obstetric
outcomes.56 The inclusion of the impact of TB in such speciﬁc
groups would be necessary, therefore, for the comprehensive
evaluation of the impact of TB on HRQOL, but to date this has not
been done.
7. Quality of life and cost-effectiveness
An assessment of the cost-effectiveness of healthcare inter-
ventions is important for the rational allocation of resources. Such
evaluations require the construction of utility weights for a given
condition, to allow the calculation of lost quality-adjusted life-
years (QALYs) or disability-adjusted life-years (DALYs) associated
with TB. The calculation of QALYs requires the allocation of a single
utility measure based on patient-level assessments such as those
discussed above. One year in perfect health is equal to 1 QALY, and
when a utility weight is applied this allows adjustment for reduced
quality of life associated with a particular condition or health state.
For example a year spent with a condition associated with ‘half’
normal health would be worth 0.5 QALYs. There are few current
studies that provide data to assist with this. The incomplete
assessment of the effect of TB on quality of life, described earlier,
may have led to a systematic underestimation of the impact of TB
in lost QALYs. This has important public health policy implica-
tions.57
As the mortality associated with TB in developed countries is
low (6.6% in the European region in 201232), failure to quantify the
long-term effects of TB on quality of life would lead to an
underestimation of lost QALYs. Studies attempting to assign values
for lost adjusted life expectancy associated with TB have used
differing methodologies and yielded variable results. Work by
Tsevat et al. in 1998, which continues to be cited as a source of
utility weights for health economic analyses, based quality of life
adjustments on ‘‘a consensus of internists in our division’’ and
resulted in a deduction of only 7 days of quality-adjusted life for
non-fatal TB.58 Similarly Porco et al. calculated there to be only8 quality-adjusted days for the hospitalized period of treatment
plus 18 quality-adjusted days over a 6-month course of
treatment.59 This would appear to underestimate the real impact
of TB disease for many in both the short and long term.27
Some health status evaluations have assumed that the quality
of life in those with cured TB returns to that of healthy subjects,
whilst others have allocated an arbitrary value for long-term ill-
health following TB. This is problematic: a study of TB patients in
Texas incorporating the effect of chronic pulmonary sequelae of TB
in an assessment of QALYs lost to TB suggested that only 4% of the
total lost QALYs result from acute TB morbidity, whilst mortality
accounted for 18% and chronic morbidity following TB was
responsible for 78% of the lost QALYs.60
An alternative strategy to the use of QALYs is the calculation of
DALYs, which requires the addition of years lost to disability and
years lost to premature death. Disability weights are calculated
using population surveys in which participants allocate prefer-
ences to different hypothetical health states, such as that used for
the Global Burden of Disease Survey (which draws on responses
from over 30 000 people61). However, as demonstrated by Diel and
Lampenius, the combination of more speciﬁc epidemiological data
and statistical modelling methods may yield more accurate (and in
this case higher) estimates for DALYs lost.62 Remaining uncertain-
ties surrounding several parameters required for these calculations
mean that this is at best an estimate (and such an assessment for
regions where less complete data exist will necessarily be less
accurate).
8. Conclusions and suggestions for future work
In summary, current evidence regarding the quality of life
associated with TB, its treatment, and long-term impact is limited.
Collecting meaningful data on HRQOL in TB presents several
challenges (see Table 4 for suggestions of what a hypothetical ideal
study of quality of life in TB would include). However, the collection
of quality of life data in future trials of therapies or preventative
measures is important, in particular in neglected areas such as the
management MDR-TB, the implications of extrapulmonary TB, and
J. Brown et al. / International Journal of Infectious Diseases 32 (2015) 68–7574the long-term health effects of TB infection. Signiﬁcant uncertainties
surrounding health status measurements translate into poor
estimates of the cost effectiveness of treatment and TB control
strategies. Given the global burden of TB infection and disease, this
must be addressed as a matter of urgency.
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